Basic information Safety Supplier Related

PFK-015

Basic information Safety Supplier Related

PFK-015 Basic information

Product Name:
PFK-015
Synonyms:
  • PFK015;PFK15;PFK 15;PFK-15
  • CS-1317
  • 2-Propen-1-one, 1-(4-pyridinyl)-3-(2-quinolinyl)-
  • 1-(4-Pyridinyl)-3-(2-quinolinyl)-2-propen-1-one PFK15
  • 1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one
  • PFK15 (PFK-015)
  • PFK-015
  • 1-(4-Pyridinyl)-3-(2-quinolinyl)-2-propen-1-one
CAS:
4382-63-2
MF:
C17H12N2O
MW:
260.29
Product Categories:
  • Inhibitors
Mol File:
4382-63-2.mol
More
Less

PFK-015 Chemical Properties

Boiling point:
464.4±45.0 °C(Predicted)
Density 
1.237±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,2-8°C
solubility 
DMSO: soluble10mg/mL, clear
form 
powder
pka
3.11±0.61(Predicted)
color 
white to beige
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
More
Less

Safety Information

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26-36/37/39
WGK Germany 
3
More
Less

PFK-015 Usage And Synthesis

Description

PFK15 (4382-63-2) is an inhibitor of the metabolic enzyme 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3).? PFKFB3 is constitutively expressed by neoplastic cells and is required for the high glycolytic rate (Warburg Effect) of these cells. PFK15 inhibits PFKFB3 (IC50?= 207 nM) without inhibiting 96 other kinases.1?PFK15 was able to potently inhibit glucose and F26BP uptake. It induced apoptosis and reduced tumor growth?in vitro?and?in vivo.?PFK15 has been shown to inhibit tumor growth in various cancer models.2,3

Uses

PFK 15 is a novel inhibitor of glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). It suppresses the glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and induces apoptosis in abnormal cells.

in vivo

PFK-015 impeds ESCC tumor growth in immunodeficient in vivo models[1].
? ? PFK-015 (0-12.5 μM, 48 h) induces tumor PD-L1 expression[1].
? ? PFK-015 (0-12.5 μM, 48 h) can cause a downregulation of immune activity against tumor cells mediated by CD8 + T cells[1].
? ? PFK-015 enhances the efficacy of ESCC by enhancing CD8 + T-cell activity combining PD-1 mAb in immunocompetent mouse models such as C57BL/6 and hu-PBMC-NOG[1].
? PFK-015 (iv, 5 mg/kg) has a satisfactory half-life, exposure, tissue distribution and reasonable clearance[2].

storage

Store at -20°C

References

[1] BRIAN F CLEM. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.[J]. Molecular Cancer Therapeutics, 2013, 12 8: 1461-1470. DOI:10.1158/1535-7163.mct-13-0097
[2] WEI ZHU. PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer[J]. PLoS ONE, 2016, 11 1. DOI:10.1371/journal.pone.0163768
[3] HUI-MIN LI. Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.[J]. Progress in brain research, 2017, 5 1: 7. DOI:10.1186/s13046-016-0481-1

PFK-015Supplier

Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
Tel
025-66113011 17798518460
Email
cfzhang@aikonchem.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Email
sales@uhnshanghai.com
Nanjing Dulai Biotechnology Co., Ltd.
Tel
025-846993838003-8003 18013301590
Email
njduly@126.com